<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00365976</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00011697</org_study_id>
    <secondary_id>ESRC 032</secondary_id>
    <nct_id>NCT00365976</nct_id>
  </id_info>
  <brief_title>Study of the Insomnia in Patients With Low Back Pain</brief_title>
  <official_title>Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether insomnia due to chronic low back pain can
      improve with use of eszopiclone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a great need to develop effective treatments for insomnia in patients with chronic
      low-back pain. Chronic low-back pain is among the most prevalent of all health complaints, is
      associated with enormous health-care and productivity costs, reduced quality of life, and
      limitation of function and is almost universally associated with insomnia (Rives and Douglas,
      2004). While it had long been believed that insomnia was a symptom of pain conditions and of
      little consequence in its' own right, a growing literature suggests that insomnia has
      important effects on the clinical course of pain syndromes (Smith and Haythornthwaite, 2004).
      While pain may disrupt sleep, it appears that problems with sleep increase pain and are
      associated with impairments in daytime function. The emerging point of view is that specific
      treatment for both pain and insomnia is needed for optimal clinical management (Smith and
      Haythornthwaite, 2004). Surprisingly, despite the fact that chronic low-back pain is the most
      common pain condition, the treatment of insomnia in this disease has never been studied. As a
      result, we propose to carry out the first double-blind placebo-controlled study of the
      treatment insomnia in patients with chronic low back pain.

      Comparison(s): We will test the hypothesis that treating the insomnia with eszopiclone 3 mg
      (ESZ) along with management of pain with naproxen 500 mg bid (NAP) will result in
      statistically significantly improved sleep compared with placebo. We also propose to test as
      a secondary hypothesis that treatment with ESZ will lead to significant improvement in pain
      and daytime function vs. placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Subjective Sleep Diary Derived Total Sleep Time (TST)</measure>
    <time_frame>Postnaprosyn baseline, Week 1, week 2, week 4</time_frame>
    <description>Nightly total sleep time was averaged from diary entries.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale Pain Ratings (VAS)</measure>
    <time_frame>Postnaprosyn baseline, Week 1, Week 2, Week 4</time_frame>
    <description>Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sleep Onset Latency (SOL)</measure>
    <time_frame>Postnaprosyn Baseline, Week 1, Week 2 week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wake Time After Sleep Onset</measure>
    <time_frame>Postnaprosyn Baseline, Week 1, Week 2 week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Awakenings</measure>
    <time_frame>Postnaprosyn Baseline, Week 1, Week 2 week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality Ratings</measure>
    <time_frame>Postnaprosyn Baseline, Week 1, Week 2 week 4</time_frame>
    <description>Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index (ISI)</measure>
    <time_frame>Prenaprosyn Baseline, Postnaprosyn Baseline, Week 1, Week 2 week 4</time_frame>
    <description>The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0-28: 0-7 (no clinical insomnia), 8-14 (subthreshold insomnia), 15-21 (insomnia of moderate severity), and 22-28 (severe insomnia).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Pain Ratings</measure>
    <time_frame>postnaprosyn Baseline, Week 1, Week 2 week 4</time_frame>
    <description>Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Roland Morris Low Back Pain Inventory (RMLBPI)</measure>
    <time_frame>prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4</time_frame>
    <description>The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 &quot;yes-no&quot; items assessing potential disabilities.
Scores range from 0 (no disability) to 24 (severe disability).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale (HAM-D-24)</measure>
    <time_frame>prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4</time_frame>
    <description>The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36 Health Survey Questionnaire (SF-36)</measure>
    <time_frame>Baseline, week 1, week 2, week 4</time_frame>
    <description>The SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The vitality sub-score assesses energy and fatigue, and ranges from 0 (worst) - 100 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anxiety Inventory (STAI)</measure>
    <time_frame>Baseline, week 1, week 2, week 4</time_frame>
    <description>Self-rating assessment of anxiety measured by STAI, state anxiety inventory (Scale 40-160, where a lower value shows a larger improvement)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Primary Insomnia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eszopiclone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eszopiclone</intervention_name>
    <description>Eszopiclone 3 mg po nightly for duration of study blind phase.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Lunesta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo nightly over duration of double blind study phase</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Diagnosis of insomnia based on DSM-IV criteria for insomnia due to a general medical
             condition (low-back pain);

               -  The insomnia must not predate the onset of low-back pain by more than 1 month;

               -  Usual nightly TST (Total Sleep Time) &lt; 6.5 hours and/or usual SOL (Sleep Onset
                  Latency) &gt; 30 minutes for the last month prior to screening;

               -  ISI (Insomnia Severity Index) &gt; 14 (at least moderate insomnia);

               -  Age 21-64 years;

               -  Greater than 40 on VAS (Visual Analog Scale) for pain (scale is 0-no pain to
                  100-worst imaginable pain);

               -  Patient Global Impression of Pain of at least 3 (on a 1-5 scale, indicating at
                  least moderate severity);

               -  reported Back pain must be greater than reported leg pain, and there must be no
                  signs of spinal nerve root compression;

               -  presence of normal motor strength on exam;

               -  duration of chronic low back pain of greater than three months;

               -  low back pain location must be inferior to T12 and superior to the gluteal fold.

        Exclusion Criteria:

          -  • Significant medical or neurological illness in excess of that which is directly
             responsible for the chronic low back pain;

               -  the presence of an active and significant psychiatric disease with a substantive
                  impact on sleep;

               -  meeting DSM-IV criteria for an Axis I disorder within the last three months, or
                  meeting criteria for substance abuse within the last 12 months;

               -  current pregnancy; history of hypersensitivity, intolerance, or contraindication
                  to Naproxen/Lansoprazole or Eszopiclone;

               -  baseline creatinine of 2.0 or greater; patient taking other medications having
                  significant renal effects (e.g. lithium, ACE inhibitor, angiotensin receptor
                  antagonist, or thiazide/loop diuretics);

               -  patients taking other anticoagulants; patients having an allergy to aspirin;
                  history of diagnosed gastric or duodenal ulcer;

               -  history of bleeding or clotting diathesis; lifetime history of myocardial
                  infarction or cerebrovascular accident;

               -  Elevated PT/PTT/INR (Prothrombin Time, Partial Thromboplastin Time, International
                  Normalized Ratio)at screening;

               -  Abnormal kidney function detected in screening labs;

               -  history of back related surgery within the past 3 months; history of
                  corticosteroid use in the past 30 days;

               -  presence of currently pending litigation or worker's compensation claim related
                  to the chronic low back pain;

               -  inability to follow study procedures or complete the study; or the use of any
                  medications that could affect sleep within 5 half-lives of screening;

               -  history of back surgery within the past 2 years with the exception of a
                  discectomy;

               -  pregnant or lactating females;

               -  women of child-bearing potential who will not agree to use approved means of
                  birth control during the trial;

               -  history of any surgery within the past one month; history of any major physical
                  trauma within the last 6 months;

               -  history of corticosteroid use within the last 90 days; diagnosis of rheumatoid or
                  psoriatic arthritis;

               -  history of fibromyalgia;

               -  presence of spondyloarthropathy;

               -  presence of sciatica;

               -  spinal stenosis;

               -  presence of any vertebral fractures, spondylolisthesis; or radicular back pain.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew D Krystal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Berry H, Bloom B, Hamilton EB, Swinson DR. Naproxen sodium, diflunisal, and placebo in the treatment of chronic back pain. Ann Rheum Dis. 1982 Apr;41(2):129-32.</citation>
    <PMID>6462116</PMID>
  </reference>
  <reference>
    <citation>Benca RM, Ancoli-Israel S, Moldofsky H. Special considerations in insomnia diagnosis and management: depressed, elderly, and chronic pain populations. J Clin Psychiatry. 2004;65 Suppl 8:26-35. Review.</citation>
    <PMID>15153065</PMID>
  </reference>
  <reference>
    <citation>Coats TL, Borenstein DG, Nangia NK, Brown MT. Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial. Clin Ther. 2004 Aug;26(8):1249-60.</citation>
    <PMID>15476906</PMID>
  </reference>
  <reference>
    <citation>Curran MP, Wellington K. Delayed-release lansoprazole plus naproxen. Drugs. 2004;64(17):1915-9; discussion 1920-1. Review.</citation>
    <PMID>15329041</PMID>
  </reference>
  <reference>
    <citation>Edinger JD, Means MK, Stechuchak KM, Olsen MK. A pilot study of inexpensive sleep-assessment devices. Behav Sleep Med. 2004;2(1):41-9.</citation>
    <PMID>15600223</PMID>
  </reference>
  <reference>
    <citation>Hägg O, Fritzell P, Nordwall A; Swedish Lumbar Spine Study Group. The clinical importance of changes in outcome scores after treatment for chronic low back pain. Eur Spine J. 2003 Feb;12(1):12-20. Epub 2002 Oct 24.</citation>
    <PMID>12592542</PMID>
  </reference>
  <reference>
    <citation>Holm I, Friis A, Storheim K, Brox JI. Measuring self-reported functional status and pain in patients with chronic low back pain by postal questionnaires: a reliability study. Spine (Phila Pa 1976). 2003 Apr 15;28(8):828-33.</citation>
    <PMID>12698128</PMID>
  </reference>
  <reference>
    <citation>Katz N, Rodgers DB, Krupa D, Reicin A. Onset of pain relief with rofecoxib in chronic low back pain: results of two four-week, randomized, placebo-controlled trials. Curr Med Res Opin. 2004 May;20(5):651-8.</citation>
    <PMID>15140330</PMID>
  </reference>
  <reference>
    <citation>Koes BW, Scholten RJ, Mens JM, Bouter LM. Efficacy of non-steroidal anti-inflammatory drugs for low back pain: a systematic review of randomised clinical trials. Ann Rheum Dis. 1997 Apr;56(4):214-23. Review.</citation>
    <PMID>9165992</PMID>
  </reference>
  <reference>
    <citation>Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, Roth T. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003 Nov 1;26(7):793-9.</citation>
    <PMID>14655910</PMID>
  </reference>
  <reference>
    <citation>Lai KC, Lam SK, Chu KM, Hui WM, Kwok KF, Wong BC, Hu HC, Wong WM, Chan OO, Chan CK. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. Aliment Pharmacol Ther. 2003 Oct 15;18(8):829-36.</citation>
    <PMID>14535877</PMID>
  </reference>
  <reference>
    <citation>Luo X, Pietrobon R, Curtis LH, Hey LA. Prescription of nonsteroidal anti-inflammatory drugs and muscle relaxants for back pain in the United States. Spine (Phila Pa 1976). 2004 Dec 1;29(23):E531-7.</citation>
    <PMID>15564901</PMID>
  </reference>
  <reference>
    <citation>Ostelo RW, de Vet HC. Clinically important outcomes in low back pain. Best Pract Res Clin Rheumatol. 2005 Aug;19(4):593-607. Review.</citation>
    <PMID>15949778</PMID>
  </reference>
  <reference>
    <citation>Pallay RM, Seger W, Adler JL, Ettlinger RE, Quaidoo EA, Lipetz R, O'Brien K, Mucciola L, Skalky CS, Petruschke RA, Bohidar NR, Geba GP. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol. 2004;33(4):257-66.</citation>
    <PMID>15370723</PMID>
  </reference>
  <reference>
    <citation>Rives PA, Douglass AB. Evaluation and treatment of low back pain in family practice. J Am Board Fam Pract. 2004 Nov-Dec;17 Suppl:S23-31.</citation>
    <PMID>15575027</PMID>
  </reference>
  <reference>
    <citation>Smith MT, Haythornthwaite JA. How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive-behavioral clinical trials literature. Sleep Med Rev. 2004 Apr;8(2):119-32. Review.</citation>
    <PMID>15033151</PMID>
  </reference>
  <reference>
    <citation>Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin. 2004 Dec;20(12):1979-91.</citation>
    <PMID>15701215</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2006</study_first_submitted>
  <study_first_submitted_qc>August 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2006</study_first_posted>
  <results_first_submitted>March 19, 2013</results_first_submitted>
  <results_first_submitted_qc>May 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 7, 2013</results_first_posted>
  <last_update_submitted>July 2, 2015</last_update_submitted>
  <last_update_submitted_qc>July 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insomnia</keyword>
  <keyword>Low Back Pain</keyword>
  <keyword>Hypnotics</keyword>
  <keyword>Eszopiclone</keyword>
  <keyword>Pain</keyword>
  <keyword>Disability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eszopiclone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Seventy adult volunteers with low back pain who met diagnostic criteria for insomnia were recruited through newspaper advertisements, posted announcements and physician referrals. Of those 70, 10 did not meet inclusion criteria, and 2 chose not to participate. The remaining 58 were randomized.</recruitment_details>
      <pre_assignment_details>Qualifying subjects were switched from their current pain regimen to naproxen and lansoprazole. We excluded those with: significant medical or neurological illness other than LBP; psychiatric disease impacting sleep; substance abuse; history of hypersensitivity or contraindication to NAP/LAN or ESZ; abnormalities on baseline laboratory tests.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Eszopiclone</title>
          <description>Eszopiclone : Eszopiclone 3 mg po nightly for duration of study blind phase.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo : Placebo nightly over duration of double blind study phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eszopiclone</title>
          <description>Eszopiclone : Eszopiclone 3 mg po nightly for duration of study blind phase.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo : Placebo nightly over duration of double blind study phase.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.7" spread="11.0"/>
                    <measurement group_id="B2" value="40.1" spread="12.8"/>
                    <measurement group_id="B3" value="43.5" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Subjective Sleep Diary Derived Total Sleep Time (TST)</title>
        <description>Nightly total sleep time was averaged from diary entries.</description>
        <time_frame>Postnaprosyn baseline, Week 1, week 2, week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone : Eszopiclone 3 mg po nightly for duration of study blind phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo nightly over duration of double blind study phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Subjective Sleep Diary Derived Total Sleep Time (TST)</title>
          <description>Nightly total sleep time was averaged from diary entries.</description>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>postnaprosyn baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316.96" spread="91.55"/>
                    <measurement group_id="O2" value="380.45" spread="81.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403.47" spread="77.67"/>
                    <measurement group_id="O2" value="375.56" spread="88.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421.97" spread="68.28"/>
                    <measurement group_id="O2" value="382.11" spread="96.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="411.97" spread="66.87"/>
                    <measurement group_id="O2" value="388.96" spread="99.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale Pain Ratings (VAS)</title>
        <description>Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain</description>
        <time_frame>Postnaprosyn baseline, Week 1, Week 2, Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone : Eszopiclone 3 mg po nightly for duration of study blind phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo nightly over duration of double blind study phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale Pain Ratings (VAS)</title>
          <description>Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Postnaprosyn Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.51" spread="16.22"/>
                    <measurement group_id="O2" value="53.79" spread="20.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.72" spread="17.13"/>
                    <measurement group_id="O2" value="51.99" spread="20.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.70" spread="18.49"/>
                    <measurement group_id="O2" value="51.25" spread="19.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.69" spread="17.92"/>
                    <measurement group_id="O2" value="51.60" spread="22.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sleep Onset Latency (SOL)</title>
        <time_frame>Postnaprosyn Baseline, Week 1, Week 2 week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone : Eszopiclone 3 mg po nightly for duration of study blind phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo nightly over duration of double blind study phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sleep Onset Latency (SOL)</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Postnaprosyn Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.28" spread="23.90"/>
                    <measurement group_id="O2" value="34.11" spread="25.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.36" spread="16.59"/>
                    <measurement group_id="O2" value="27.00" spread="18.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.50" spread="12.33"/>
                    <measurement group_id="O2" value="23.10" spread="19.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.28" spread="12.95"/>
                    <measurement group_id="O2" value="19.91" spread="12.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wake Time After Sleep Onset</title>
        <time_frame>Postnaprosyn Baseline, Week 1, Week 2 week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone : Eszopiclone 3 mg po nightly for duration of study blind phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo nightly over duration of double blind study phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Wake Time After Sleep Onset</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Postnaprosyn Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.51" spread="55.91"/>
                    <measurement group_id="O2" value="81.43" spread="54.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.34" spread="32.62"/>
                    <measurement group_id="O2" value="76.71" spread="65.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.07" spread="22.21"/>
                    <measurement group_id="O2" value="81.32" spread="76.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.74" spread="28.44"/>
                    <measurement group_id="O2" value="76.18" spread="65.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Awakenings</title>
        <time_frame>Postnaprosyn Baseline, Week 1, Week 2 week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone : Eszopiclone 3 mg po nightly for duration of study blind phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo nightly over duration of double blind study phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Awakenings</title>
          <units>awakenings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Postnaprosyn Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="1.48"/>
                    <measurement group_id="O2" value="2.08" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="1.02"/>
                    <measurement group_id="O2" value="1.98" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="0.99"/>
                    <measurement group_id="O2" value="2.13" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="1.01"/>
                    <measurement group_id="O2" value="2.34" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality Ratings</title>
        <description>Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep</description>
        <time_frame>Postnaprosyn Baseline, Week 1, Week 2 week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone : Eszopiclone 3 mg po nightly for duration of study blind phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo nightly over duration of double blind study phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality Ratings</title>
          <description>Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Postnaprosyn Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.52" spread="1.45"/>
                    <measurement group_id="O2" value="4.44" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.99" spread="1.43"/>
                    <measurement group_id="O2" value="4.90" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.18" spread="1.45"/>
                    <measurement group_id="O2" value="5.33" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.38" spread="1.66"/>
                    <measurement group_id="O2" value="5.29" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insomnia Severity Index (ISI)</title>
        <description>The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0–28: 0–7 (no clinical insomnia), 8–14 (subthreshold insomnia), 15–21 (insomnia of moderate severity), and 22–28 (severe insomnia).</description>
        <time_frame>Prenaprosyn Baseline, Postnaprosyn Baseline, Week 1, Week 2 week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone : Eszopiclone 3 mg po nightly for duration of study blind phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo nightly over duration of double blind study phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Insomnia Severity Index (ISI)</title>
          <description>The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0–28: 0–7 (no clinical insomnia), 8–14 (subthreshold insomnia), 15–21 (insomnia of moderate severity), and 22–28 (severe insomnia).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prenaprosyn Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.85" spread="4.01"/>
                    <measurement group_id="O2" value="20.26" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postnaprosyn baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.00" spread="3.41"/>
                    <measurement group_id="O2" value="16.78" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.28" spread="6.10"/>
                    <measurement group_id="O2" value="12.85" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.61" spread="6.60"/>
                    <measurement group_id="O2" value="12.74" spread="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.38" spread="6.42"/>
                    <measurement group_id="O2" value="13.75" spread="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Pain Ratings</title>
        <description>Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain)</description>
        <time_frame>postnaprosyn Baseline, Week 1, Week 2 week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone : Eszopiclone 3 mg po nightly for duration of study blind phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo nightly over duration of double blind study phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Pain Ratings</title>
          <description>Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>postnaprosyn Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="0.95"/>
                    <measurement group_id="O2" value="3.90" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" spread="1.17"/>
                    <measurement group_id="O2" value="3.82" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="1.27"/>
                    <measurement group_id="O2" value="4.01" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" spread="1.28"/>
                    <measurement group_id="O2" value="3.80" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Roland Morris Low Back Pain Inventory (RMLBPI)</title>
        <description>The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 “yes-no” items assessing potential disabilities.
Scores range from 0 (no disability) to 24 (severe disability).</description>
        <time_frame>prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone : Eszopiclone 3 mg po nightly for duration of study blind phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo nightly over duration of double blind study phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Roland Morris Low Back Pain Inventory (RMLBPI)</title>
          <description>The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 “yes-no” items assessing potential disabilities.
Scores range from 0 (no disability) to 24 (severe disability).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>prenaprosyn Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.27" spread="5.70"/>
                    <measurement group_id="O2" value="11.33" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postnaprosyn Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.97" spread="5.55"/>
                    <measurement group_id="O2" value="10.30" spread="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.10" spread="6.37"/>
                    <measurement group_id="O2" value="9.05" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.63" spread="6.34"/>
                    <measurement group_id="O2" value="9.32" spread="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.59" spread="5.49"/>
                    <measurement group_id="O2" value="7.94" spread="6.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Depression Rating Scale (HAM-D-24)</title>
        <description>The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.</description>
        <time_frame>prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone : Eszopiclone 3 mg po nightly for duration of study blind phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo nightly over duration of double blind study phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale (HAM-D-24)</title>
          <description>The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>prenaprosyn Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" spread="2.26"/>
                    <measurement group_id="O2" value="7.10" spread="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postnaprosyn Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.38" spread="2.37"/>
                    <measurement group_id="O2" value="6.57" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.54" spread="3.71"/>
                    <measurement group_id="O2" value="5.53" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" spread="3.50"/>
                    <measurement group_id="O2" value="5.07" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" spread="2.61"/>
                    <measurement group_id="O2" value="6.21" spread="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form 36 Health Survey Questionnaire (SF-36)</title>
        <description>The SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The vitality sub-score assesses energy and fatigue, and ranges from 0 (worst) - 100 (best).</description>
        <time_frame>Baseline, week 1, week 2, week 4</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone : Eszopiclone 3 mg po nightly for duration of study blind phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo nightly over duration of double blind study phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form 36 Health Survey Questionnaire (SF-36)</title>
          <description>The SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The vitality sub-score assesses energy and fatigue, and ranges from 0 (worst) - 100 (best).</description>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>State-Trait Anxiety Inventory (STAI)</title>
        <description>Self-rating assessment of anxiety measured by STAI, state anxiety inventory (Scale 40-160, where a lower value shows a larger improvement)</description>
        <time_frame>Baseline, week 1, week 2, week 4</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone : Eszopiclone 3 mg po nightly for duration of study blind phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo nightly over duration of double blind study phase.</description>
          </group>
        </group_list>
        <measure>
          <title>State-Trait Anxiety Inventory (STAI)</title>
          <description>Self-rating assessment of anxiety measured by STAI, state anxiety inventory (Scale 40-160, where a lower value shows a larger improvement)</description>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Eszopiclone</title>
          <description>Eszopiclone : Eszopiclone 3 mg po nightly for duration of study blind phase.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo : Placebo nightly over duration of double blind study phase.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We obtained only self-reported sleep outcomes.
The period of double-blind treatment was relatively short.
We excluded all subjects who might have required opioid therapy to manage their pain which limits study generalizability.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jenny Bridgers, CRC</name_or_title>
      <organization>Duke University</organization>
      <phone>919-684-0752</phone>
      <email>jenny.bridgers@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

